The growth outlook on Indian market continues to remain optimistic with 15-18% growth
Dublin, Ireland (PRWEB) February 28, 2013
Research and Markets has announced the addition of the "Global Pharmaceutical & Biotechnology Outlook 2013: India Pharma" report to their offering.
India pharma rode on the wave of bunched up patent expiries in the US with many Para IV launches in 2012. In addition, it also benefited from the continuing high teen growth of Indian pharma market. With patent expiries in the US dwindling from $30b in 2012 to $10b in 2013 (small molecules), Indian generic companies will now need to focus on complex generics that offer sustainability of earnings. Locally acting drugs and targeted drug delivery products make up for the bulk of complex formulation generics. We have analyzed this space and have provided a fairly comprehensive list of products falling under these categories indicating that topical drugs remains the most near term opportunity for generics. Inhalers offer the most lucrative opportunity, though not before 2016.
The growth outlook on Indian market continues to remain optimistic with 15-18% growth. This is based on the silent reforms in India that started with implementation of a strict GMP (Good Manufacturing Practices) in 2005, continued with implementation of GLP (Good Laboratories Practices) in 2011 and now the bar coding norms at primary and secondary levels. All these continue to put pressure on the very small manufacturer ultimately leading to industry consolidation – something that augurs well for world’s most fragmented pharma market. This report "Global Pharmaceutical & Biotechnology Outlook for 2013: India Pharma" does not see any negative impact due to the newly announced National Pharma Pricing Policy (NPPP) due to its emphasis on market price based pricing policy.
The reports top pick remains Sun Pharma as it remains the best positioned to tide over the patent cliff with its latest acquisitions, DUSA and URL Pharma. A strong balance sheet further allows it to acquire more such high value targets. Natco Pharma has been recommended for its focus on complex generics like Copaxone, Revlimid and Tamiflu. Besides this, its domestic market strategy targeted at gaining Compulsory License on high value oncology products too remains lucrative.
Key Topics Covered
1. Complex Formulations – Scope and Opportunity in US market
2. Liposomal Drugs: Opportunities for Generic Companies
3. Colon Targeted Drugs: Opportunities for Generic Companies
4. Transdermal Drugs: Opportunities for Generic Companies
5. Topical Dermatological Drugs: Opportunities for Generic Companies
6. Inhalers: Opportunities for Generic Companies
7. Reforms and Consolidation Continues in Domestic Market
8. New Pharma Pricing Policy – Neutral to Positive for the Industry
9. IPCA: Momentum Continues
10. Natco: Entering the Big League Through Multi Pronged Strategy
11. Sun Pharma: Balance Sheet Leveraging at Play
12. Aurobindo: Still Not Out of the Woods
13. Dishman: Management Accepts The Limitations of Pure Play Crams
14. Biocon: Expenses More Visible than Growth Drivers
15. Cadila Healthcare: In a Phase of Consolidation
16. Cipla: Weakness in Regulated Markets Persists
17. Dr Reddy’s Lab: Moderate Earnings Due to High Base and Upfront Investment
18. Lupin: Margin Worry on Base Business
19. Ranbaxy: Improvement in Base Business Margin is Still Uncertain
For more information visit http://www.researchandmarkets.com/research/vrztpz/global
Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716